About

Board of Directors

Noel Doheny

CEO, Epigenomics USA

Noel Doheny has over 35 years of experience in the global diagnostics market. Following a successful sales career at Gilford Instruments, he assumed increasingly significant roles within the commercial organization as the organization was acquired by Corning. These included Marketing management, Market Development and General Management in chemistry, quality control and coagulation. He assumed the lead commercial leadership role at BioStar, a VC-backed, point-of-care infectious pathogen assay company. The company was acquired by Thermo Electron, where Doheny was CEO of BioStar and led all strategic efforts for clinical chemistry and pathology for Thermo.

 

Doheny moved into the Molecular Diagnostic field as SVP at Qiagen for diagnostics, leading the transition from sample prep to assay products. Later he led the DX efforts at Affymetrix by completing multiple cancer assays relationships. He then became CEO of Opgen, Inc a VC genome assembly company.

 

Currently he is CEO of Epigenomics, Inc., a leader in blood-based screening for colon cancer, where he manages all US activities and global business development and partnership development.

 

He serves as a Commercial Advisor to Sequenta, a market expert for Price Waterhouse Cooper and is an industry advisor to DDN News. He received his undergraduate degrees from West Virginia University where he was Phi Beta Kappa in both chemistry and biology. He completed graduate work at Georgetown University in biochemistry and in entrepreneurship at Case Western University.

Expand

Mike Hoerres

CEO, Cernostics

Mike Hoerres brings more than 30 years of experience generating revenue and building new markets in the life sciences industry to his role as CEO of Cernostics. In his role as CEO Mike leads overall strategic direction for the company, and applies his passion for improving healthcare through genomic and proteomic technologies to the company.  Previously Mike was a Principal at Geisinger Ventures, the venture arm of Geisinger Health System, where Mike led partnering activities with life science companies focused on diagnostic development and personalized medicine. Geisinger's focus on innovation in personalized healthcare led to an investment and collaboration agreement with Cernostics in 2010. Mike has also served in a variety of sales, marketing and business development roles at Affymetrix, Incyte Genomics, Source MDx, and Stratagene (acquired by Agilent).

 

Mike currently serves on the Board of Directors of Pennsylvania Bio, Pennylvania's largest life science trade organization supporting the life science community through advocacy, enterprise support and collaboration, and the Pennsylvania Life Sciences Institute. Mike holds a BS in biochemistry of University of Wisconsin and a Master of Science in molecular immunology from San Diego State University.

Expand

Tom Willis, Ph.D.

Partner, Illumina Ventures

Tom Willis has been an entrepreneur in the genomics industry for the past 15 years during which time he founded and successfully exited two startups in the genomic tools and diagnostic space.  After having received his undergraduate and graduate degrees in physics from Yale and Stanford respectively, he directed technology development efforts at the Stanford Genome Technology Center during the human genome project. He left Stanford in 2001 to found his first venture, ParAllele BioScience where he served as the founding CEO. After two rounds of venture financing and the successful development and commercialization of high throughput genotyping tools, ParAllele was acquired by Affymetrix in 2005.

Tom founded his second venture, Sequenta in 2008. As Sequenta’s CEO, Tom and his team developed and commercialized a sequencing based platform for assessment of the human immune repertoire. Its lead diagnostic indication, clonoSEQ, allows the assessment of residual disease in leukemia and lymphoma, has been adopted by major cancer centers and has been established as standard of care in NCCN guidelines. In 2015 Sequenta merged with Adaptive Biotechnologies to build an immune platform company valued at over $1bn. Tom remains on the board of Adaptive. In addition to his own ventures, Tom has served on the boards of several other biotech startups.

Expand
Customer Service

Mon-Fri 9am-5pm (EST)

×